BCL2 and B-cell chronic lymphocytic leukemia: In recent years, the therapeutic strategies for CLL have undergone great improvement thanks to the development of new small molecules for the inhibition of BTK and BCL‐2 proteins, such as ibrutinib, acalabrutinib, or venetoclax [25, 26].